In the last trading session, 2.04 million shares of the Cognition Therapeutics Inc (NASDAQ:CGTX) were traded, and its beta was 0.88. Most recently the company’s share price was $0.26, and it changed around -$0.04 or -12.93% from the last close, which brings the market valuation of the company to $16.03M. CGTX currently trades at a discount to its 52-week high of $2.63, offering almost -911.54% off that amount. The share price’s 52-week low was $0.28, which indicates that the current value has fallen by an impressive -7.69% since then. We note from Cognition Therapeutics Inc’s average daily trading volume that its 10-day average is 0.65 million shares, with the 3-month average coming to 1.40 million.
Cognition Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended CGTX as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Cognition Therapeutics Inc is expected to report earnings per share of -0.1 for the current quarter.
Cognition Therapeutics Inc (NASDAQ:CGTX) trade information
Instantly CGTX has showed a red trend with a performance of -12.93% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.3390 on recent trading dayincreased the stock’s daily price by 23.3%. The company’s shares are currently down -63.14% year-to-date, but still down -21.67% over the last five days. On the other hand, Cognition Therapeutics Inc (NASDAQ:CGTX) is -40.95% down in the 30-day period. We can see from the shorts that 0.91 million shares have been sold at a short interest cover period of 1.71 day(s).
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -16.44%. Cognition Therapeutics Inc earnings are expected to increase by 52.62% in 2025, but the outlook is positive 29.61% per year for the next five years.
CGTX Dividends
Cognition Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-06.
Cognition Therapeutics Inc (NASDAQ:CGTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.59% of Cognition Therapeutics Inc shares, and 18.80% of them are in the hands of institutional investors. The stock currently has a share float of 18.91%. Cognition Therapeutics Inc stock is held by 53.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 2.8644% of the shares, which is about 1.15 million shares worth $1.9 million.
AWM INVESTMENT COMPANY, INC., with 1.6224% or 0.65 million shares worth $1.08 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.01 shares worth $0.26 million, making up 1.63% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 200.58 shares worth around $51849.0, which represents about 0.32% of the total shares outstanding.
